JTA-009, a fully human antibody against human AILIM/ICOS, ameliorates graft-vs-host reaction in SCID mice grafted with human PBMCs

Experimental Hematology

Volumn 36, Issue 11, 2008, Pages 1514-1523

  Tajima, Nobuyuki ^a   Tezuka, Katsunari ^a   Tanimoto, Atsuo ^a   Miyai, Atsuko ^a   Tanimoto, Minako ^a   Maruhashi, Junji ^a   Watanabe, Yoshihiro ^b  

^a Central Pharmaceutical Research Institute   (Japan)

^b Central Pharmaceutical Institute   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE; ALLOANTIGEN; B7 ANTIGEN; BLOCKING ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN; JTA 009; MONOCLONAL ANTIBODY CD28; UNCLASSIFIED DRUG; ABATACEPT; ANTIBODY CONJUGATE; INDUCIBLE T CELL CO STIMULATOR; INDUCIBLE T-CELL CO-STIMULATOR; JTA-009; MONOCLONAL ANTIBODY; T LYMPHOCYTE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL CULTURE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; EFFECTOR CELL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCID MOUSE; SPLEEN; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; ANIMAL; BLOOD; DISEASE MODEL; IMMUNOLOGY; MONONUCLEAR CELL; MOUSE MUTANT; PHYSIOLOGY; TRANSPLANTATION; XENOGRAFT;

MURINAE; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNOCONJUGATES; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MICE; MICE, SCID; TRANSPLANTATION, HETEROLOGOUS;

EID: 53749098778     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.06.004     Document Type: Article

References (44)

1. Rudd C.E., and Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signaling. Nat Rev Immunol 3 (2003) 544-556
2. Riley J.L., and June C.H. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 105 (2005) 13-21
3. Tamatani T., Tezuka K., and Hanzawa-Higuchi N. AILIM/ICOS: a novel lymphocyte adhesion molecule. Int Immunol 12 (2000) 51-55
4. Tezuka K., Tsuji T., Hirano D., et al. Identification and characterization of rat AILIM/ICOS, a novel T-cell costimulatory molecule, related to the CD28/CTLA4 family. Biochem Biophys Res Commun 276 (2000) 335-345
5. Hutloff A., Dittrich A.M., Beier K.C., et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397 (1999) 263-266
6. Swallow M.M., Wallin J.J., and Sha W.C. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity 11 (1999) 423-432
7. Yoshinaga S.K., Whoriskey J.S., Khare S.D., et al. T-cell costimulation through B7RP-1 and ICOS. Nature 402 (1999) 827-832
8. Aicher A., Hayden-Ledbetter M., Brady W.A., et al. Characterization of human inducible costimulator ligand expression and function. J Immunol 164 (2000) 4689-4696
9. Yoshinaga S.K., Zhang M., Pistillo J., et al. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. Int Immunol 12 (2000) 1439-1447
10. Kosuge H., Suzuki J., Haraguchi G., et al. Critical role of inducible costimulator signaling in the development of arteriosclerosis. Arterioscler Thromb Vasc Biol 26 (2006) 2660-2665
11. Khayyamian S., Hutloff A., Buchner K., et al. ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory CD4 + T cells. Proc Natl Acad Sci U S A 99 (2002) 6198-6203
12. Nakazawa A., Dotan I., Brimnes J., et al. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology 126 (2004) 1347-1357
13. Dong C., Juedes A.E., Temann U.A., et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409 (2001) 97-101
14. McAdam A.J., Greenwald R.J., Levin M.A., et al. ICOS is critical for CD40-mediated antibody class switching. Nature 409 (2001) 102-104
15. Tafuri A., Shahinian A., Bladt F., et al. ICOS is essential for effective T-helper-cell responses. Nature 409 (2001) 105-108
16. Lohning M., Hutloff A., Kallinich T., et al. Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J Exp Med 197 (2003) 181-193
17. Liu X., Bau X.F., Wen J., et al. B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo. J Exp Med 194 (2001) 1339-1348
18. Coyle A.J., Lehar S., Lloyd C., et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 13 (2000) 95-105
19. Liang L., and Sha W.C. The right place at the right time: novel B7 family members regulate effector T cell responses. Curr Opin Immunol 14 (2002) 384-390
20. Gonzalo J.A., Tian J., Delaney T., et al. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat Immunol 2 (2001) 597-604
21. Nurieva R.I., Treuting P., Duong J., Flavell R.A., and Dong C. Inducible costimulator is essential for collagen-induced arthritis. J Clin Invest 111 (2003) 701-706
22. Iwai H., Kozono Y., Hirose S., et al. Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation. J Immunol 169 (2002) 4332-4339
23. Ozkaynak E., Gao W., Shemmeri N., et al. Importance of ICOS-B7RP-1costimulation in acute and chronic allograft rejection. Nat Immunol 2 (2001) 591-596
24. Harada H., Salama A.D., Sho M., et al. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest 112 (2003) 234-243
25. Nanji S.A., Hancock W.W., Anderson C.C., et al. Multiple combination therapies involving blockade of ICOS/B7RP-1costimulation facilitate long-term islet allograft survival. Am J Transplant 4 (2004) 526-536
26. Taylor P.A., Panoskaltsis-Mortari A., Freeman G.J., et al. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells downregulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood 105 (2005) 3372-3380
27. Yu X.Z., Liang Y., Nurieva R.I., Guo F., Anasetti C., and Dong C. Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells. J Immunol 176 (2006) 7394-7401
28. Rottman J.B., Smith T., Tonra J.R., et al. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol 2 (2001) 605-611
29. Sporici R.A., Beswick R.L., von Allmen C., et al. ICOS ligand costimulation is required for T-cell encephalitogenicity. Clin Immunol 100 (2001) 277-288
30. Kosuge H., Suzuki J., Gotoh R., et al. Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation 75 (2003) 1374-1379
31. Hubbard V.M., Eng J.M., Ramirez-Montagut T., et al. Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation. Blood 106 (2005) 3285-3292
32. Mestas J., and Hughes C.C. Of mice and not men: differences between mouse and human immunology. J Immunol 172 (2004) 2731-2738
33. Mosier D.E., Gulizia R.J., Baird S.M., and Wilson D.B. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335 (1988) 256-259
34. Sandhu J., Shpitz B., Gallinger S., and Hozumi N. Human primary immune response in SCID mice engrafted with human peripheral blood lymphocytes. J Immunol 152 (1994) 3806-3813
35. Sandhu J.S., Gorczynski R., Shpitz B., Gallinger S., Nguyen H.P., and Hozumi N. A human model of xenogeneic graft-versus-host disease in scid mice engrafted with human peripheral blood lymphocytes. Transplantation 60 (1995) 179-184
36. Mendez M.J., Green L.L., Corvalan J.R., et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 15 (1997) 146-156
37. Sakamoto S., Tezuka K., Tsuji T., Hori N., and Tamatani T. AILIM/ICOS: its expression and functional analysis with monoclonal antibodies. Hybrid Hybridomics 20 (2001) 293-303
38. Tajima N., Tezuka K., Tanaka M., et al. Critical role of activation-inducible lymphocyte immunomediatory molecule inducible costimulater in the effector function of human T cells: a comparative in vitro study of effects of its blockade and CD28 blockade in human beings and monkeys. Hum Immunol 69 (2008) 399-408
39. Barrett A.J., Rezvani K., Solomon S., et al. New developments in allotransplant immunology. Hematology Am Soc Hematol Educ Prog (2003) 350-371
40. Duffner U.A., Maeda Y., Cooke K.R., et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 172 (2004) 7393-7398
41. Tojo A., Ooi J., Tomonari A., et al. Expression of AILIM/ICOS in tissue-infiltrating lymphocytes in GvHD. Int J Hematol 73 suppl 1 (2001) 86
42. Wallin J.J., Liang L., Bakardjiev A., and Sha W.C. Enhancement of CD8 + T cell responses by ICOS/B7h costimulation. J Immunol 167 (2001) 132-139
43. Riley J.L., Blair P.J., Musser J.T., et al. ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. J Immunol 166 (2001) 4943-4948
44. Anderson B.E., McNiff J.M., Jain D., Blazar B.R., Shlomchik W.D., and Shlomchik M.J. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 105 (2005) 2227-2234